GB532822A
(en)
|
1939-08-11 |
1941-01-31 |
John David Kendall |
Improvements in and relating to the production of ª‡-coumarilyl and ª‡-thionaphthenoyl-acetic acid esters
|
US4342689A
(en)
|
1980-04-28 |
1982-08-03 |
American Cyanamid Company |
ω-Heteroaroyl(propionyl or butyryl)-L-prolines
|
US4299769A
(en)
|
1980-04-28 |
1981-11-10 |
American Cyanamid Company |
ω-Heteroaroyl(propionyl or butyryl)-L-prolines
|
US4342690A
(en)
|
1980-04-28 |
1982-08-03 |
American Cyanamid Company |
ω-Heteroaroyl(propionyl or butyryl)-L-prolines
|
US4342691A
(en)
|
1980-04-28 |
1982-08-03 |
American Cyanamid Company |
ω-Heteroaroyl(propionyl or butyryl)-L-prolines
|
EP0146243A1
(en)
|
1983-10-31 |
1985-06-26 |
Merck Frosst Canada Inc. |
Lipoxygenase inhibitors
|
EP0350990B1
(en)
|
1988-07-11 |
1995-09-20 |
Akzo Nobel N.V. |
Pyridazinone derivatives
|
ATE188379T1
(de)
|
1992-10-14 |
2000-01-15 |
Merck & Co Inc |
Fibrinogenrezeptor-antagonisten
|
US5569655A
(en)
*
|
1993-09-14 |
1996-10-29 |
Sterling Winthrop Inc. |
Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
|
CA2333771A1
(en)
|
1998-06-03 |
1999-12-09 |
Mark W. Embrey |
Hiv integrase inhibitors
|
US6262055B1
(en)
|
1998-06-03 |
2001-07-17 |
Merck & Co., Inc. |
HIV integrase inhibitors
|
PE20010306A1
(es)
|
1999-07-02 |
2001-03-29 |
Agouron Pharma |
Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
|
GB0018891D0
(en)
|
2000-08-01 |
2000-09-20 |
Novartis Ag |
Organic compounds
|
AU2001248701A1
(en)
|
2000-03-24 |
2001-10-03 |
Methylgene, Inc. |
Inhibitors of histone deacetylase
|
AU2002234755A1
(en)
|
2001-02-26 |
2002-09-12 |
Pharma Pacific Pty Ltd |
Interferon-alpha induced gene
|
ES2654064T3
(es)
|
2002-07-03 |
2024-03-13 |
Ono Pharmaceutical Co |
Composiciones inmunopotenciadoras que comprenden anticuerpos anti-PD-L1
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
US7563869B2
(en)
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
AU2004268012B2
(en)
|
2003-09-02 |
2008-11-20 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
AU2005222626B2
(en)
|
2004-03-15 |
2010-05-20 |
Karagen Pharmaceuticals, Inc. |
A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
|
CN101213297B
(zh)
|
2005-05-09 |
2013-02-13 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法
|
KR101411165B1
(ko)
|
2005-07-01 |
2014-06-25 |
메다렉스, 엘.엘.시. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
|
EP1782826A1
(en)
|
2005-11-08 |
2007-05-09 |
GBF Gesellschaft für Biotechnologische Forschung mbH |
PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
|
KR101586617B1
(ko)
|
2007-06-18 |
2016-01-20 |
머크 샤프 앤 도메 비.브이. |
사람 프로그램된 사멸 수용체 pd-1에 대한 항체
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
CN102203125A
(zh)
|
2008-08-25 |
2011-09-28 |
安普利穆尼股份有限公司 |
Pd-1拮抗剂及其使用方法
|
MX349463B
(es)
|
2008-09-26 |
2017-07-31 |
Univ Emory |
Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
|
US8664255B2
(en)
|
2008-10-20 |
2014-03-04 |
The Texas A&M University System |
Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof
|
PE20120341A1
(es)
|
2008-12-09 |
2012-04-24 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
WO2012068702A1
(zh)
|
2010-11-23 |
2012-05-31 |
中国医学科学院医药生物技术研究所 |
苯并五元不饱和杂环类化合物及其制备方法
|
JP5887947B2
(ja)
|
2011-03-28 |
2016-03-16 |
ソニー株式会社 |
透明導電膜、ヒータ、タッチパネル、太陽電池、有機el装置、液晶装置および電子ペーパ
|
EP2697242B1
(en)
|
2011-04-13 |
2018-10-03 |
Merck Sharp & Dohme Corp. |
2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
EA026924B1
(ru)
|
2011-08-01 |
2017-05-31 |
Дженентек, Инк. |
Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
|
WO2013185052A1
(en)
|
2012-06-08 |
2013-12-12 |
Aduro Biotech |
Compostions and methods for cancer immunotherapy
|
CN103840995B
(zh)
|
2012-11-26 |
2017-10-24 |
华为技术有限公司 |
Ip报文处理方法、装置及网络系统
|
MX361680B
(es)
|
2012-12-13 |
2018-12-13 |
Aduro Biotech Inc |
Composiciones que comprenden dinucleótidos de purina cíclicos que tienen estereoquímicas definidas y métodos para su preparación y uso.
|
WO2014099941A1
(en)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
DK2934598T3
(en)
|
2012-12-19 |
2018-07-23 |
Univ Texas |
PHARMACEUTICAL TARGETING OF A CYCLIC MAMMAL DI DI NUCLEOTIDE SIGNAL ROAD
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
EP2992000B1
(en)
|
2013-05-03 |
2020-07-08 |
The Regents of The University of California |
Cyclic di-nucleotide induction of type i interferon
|
PL2996473T3
(pl)
|
2013-05-18 |
2020-06-01 |
Aduro Biotech, Inc. |
Kompozycje i sposoby aktywacji sygnałowania zależnego od „stymulatora genu interferonu”
|
US9549944B2
(en)
|
2013-05-18 |
2017-01-24 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
|
WO2014189806A1
(en)
|
2013-05-18 |
2014-11-27 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
|
MY179503A
(en)
|
2013-07-30 |
2020-11-09 |
Janssen Sciences Ireland Uc |
Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
|
EP3027227A4
(en)
|
2013-07-31 |
2018-05-23 |
Memorial Sloan Kettering Cancer Center |
Sting crystals and modulators
|
WO2015077354A1
(en)
*
|
2013-11-19 |
2015-05-28 |
The University Of Chicago |
Use of sting agonist as cancer treatment
|
CA2931146C
(en)
|
2013-11-22 |
2022-06-28 |
Brock University |
Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
|
US9315523B2
(en)
|
2013-12-06 |
2016-04-19 |
Rutgers, The State University Of New Jersey |
Cyclic dinucleosides
|
WO2015143712A1
(en)
|
2014-03-28 |
2015-10-01 |
Merck Sharp & Dohme Corp. |
4'-substituted nucleoside reverse transcriptase inhibitors
|
EP3131914B1
(en)
|
2014-04-16 |
2023-05-10 |
Idenix Pharmaceuticals LLC |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
CN103908468B
(zh)
|
2014-04-21 |
2017-02-08 |
上海捌加壹医药科技有限公司 |
环二核苷酸cGAMP在制备抗肿瘤药物中的应用
|
PE20170198A1
(es)
|
2014-06-04 |
2017-04-08 |
Glaxosmithkline Ip Dev Ltd |
Dinucleotidos ciclicos como moduladores de sting
|
WO2015189117A1
(de)
|
2014-06-12 |
2015-12-17 |
Bayer Pharma Aktiengesellschaft |
Heterobicyclisch substituierte 4-oxobutansäure-derivate und ihre verwendung
|
ES2764178T3
(es)
|
2014-12-16 |
2020-06-02 |
Kayla Therapeutics |
Dinucleótidos cíclicos fluorados para inducción de citocinas
|
EP3233191A1
(en)
|
2014-12-16 |
2017-10-25 |
Invivogen |
Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
|
US20180344758A1
(en)
|
2014-12-17 |
2018-12-06 |
Lipogen Llc |
Method of Treating Cancer with cGAMP or cGAsMP
|
GB201501462D0
(en)
|
2015-01-29 |
2015-03-18 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
WO2016145102A1
(en)
|
2015-03-10 |
2016-09-15 |
Aduro Biotech, Inc. |
Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
|
TW201717968A
(zh)
|
2015-07-14 |
2017-06-01 |
春季銀行製藥公司 |
誘導rig-i和其他模式辨識受體之化合物及組成物
|
EP3325473A4
(en)
|
2015-07-22 |
2019-06-26 |
The Royal Institution for the Advancement of Learning / McGill University |
Compounds and uses thereof in the treatment of cancer and other medical disorders
|
MX2018001814A
(es)
|
2015-08-13 |
2018-05-07 |
Merck Sharp & Dohme |
Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon.
|
US9809597B2
(en)
|
2015-08-20 |
2017-11-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy
|
UY36969A
(es)
|
2015-10-28 |
2017-05-31 |
Novartis Ag |
Composiciones y métodos para activar la señalización dependiente del estimulador del gen de interferon
|
CR20180286A
(es)
|
2015-12-03 |
2018-07-16 |
Glaxosmithkline Ip Dev Ltd |
Dinucleotidos de purina cíclicos como moduladores de sting
|
CA3007311A1
(en)
|
2015-12-07 |
2017-06-15 |
Opi Vi - Ip Holdco Llc |
Compositions of antibody construct-agonist conjugates and methods of use thereof
|
MX2018008266A
(es)
|
2016-01-11 |
2019-01-31 |
Innate Tumor Immunity Inc |
Dinucleotidos ciclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferon (sting) tales como cancer.
|
WO2017123657A1
(en)
|
2016-01-11 |
2017-07-20 |
Gary Glick |
Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
|
SG10201912074PA
(en)
|
2016-03-18 |
2020-02-27 |
Immune Sensor Llc |
Cyclic di-nucleotide compounds and methods of use
|
WO2017175156A1
(en)
*
|
2016-04-07 |
2017-10-12 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
EP3440076B1
(en)
|
2016-04-07 |
2022-06-01 |
GlaxoSmithKline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
WO2017216726A1
(en)
|
2016-06-13 |
2017-12-21 |
Glaxosmithkline Intellectual Property Development Limited |
Substituted pyridines as inhibitors of dnmt1
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
SG10202008647TA
(en)
|
2016-10-04 |
2020-10-29 |
Merck Sharp & Dohme |
BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
|
WO2019195063A1
(en)
|
2018-04-03 |
2019-10-10 |
Merck Sharp & Dohme Corp. |
Aza-benzothiophene compounds as sting agonists
|